美国2型糖尿病患者血浆致动脉粥样硬化指数(AIP)与肝脂肪变性和肝纤维化之间的关联:一项大型横断面研究
Association between the Atherogenic Index of Plasma (AIP) and Hepatic Steatosis and Fibrosis in American Patients with Type 2 Diabetes Mellitus: A Large Cross-Sectional Study
DOI: 10.12677/acm.2024.1472125, PDF,   
作者: 王帅帅, 阮士苗, 张文忠*:青岛大学附属医院心血管内科,山东 青岛;孙建秀:青岛市第八人民医院心血管内科,山东 青岛
关键词: 2型糖尿病血浆致动脉粥样硬化指数非酒精性脂肪肝肝脂肪变肝纤维化NHANESType 2 Diabetes Mellitus Atherogenic Index of Plasma NAFLD Hepatic Steatosis Liver Fibrosis NHANES
摘要: 目的:血浆致动脉粥样硬化指数(AIP)是反映脂质代谢的新指标。2型糖尿病(T2DM)是发生非酒精性脂肪肝(NAFLD)的高危因素。本研究的主要目的是探讨AIP与美国T2DM患者肝脏脂肪变性和肝纤维化之间的潜在相关性。方法:使用2017~2020年全国健康与营养检查调查(NHANES)的数据集进行横断面调查。构建三个模型,采用回归分析检验AIP与受控衰减参数(CAP)、肝脏硬度测量(LSM)以及NAFLD之间的线性关系,将AIP划分四个等级并进行趋势性检验。采用限制性立方样条图(RCS)来描述它们之间的非线性关系。以上所有统计分析都经过加权处理。结果:这项以美国T2DM患者为基础的研究纳入1170人。在多元线性回归和逻辑回归分析中,AIP*10与CAP [β (95% CI), 3.18 (0.41~5.96), P = 0.033]、NAFLD [OR (95% CI), 1.16 (1.02~1.33), P = 0.035]均呈显著正相关,趋势性检验存在统计学意义,但AIP与LSM [β (95% CI), 0.04 (−1.35~1.42), P = 0.947]的关系并不显著。RCS分析显示AIP和CAP之间呈S型非线性关系(P-overall < 0.001, P-non-linear = 0.036),并且随着AIP的升高,男性比女性有更严重的肝脏脂肪变。结论:AIP与T2DM患者肝脏脂肪变性之间存在显著正相关,它或许可以成为预测NAFLD发生的一项无创指标。然而,并未发现AIP与肝纤维化之间存在任何关联。
Abstract: Purpose: Plasma atherogenic index (AIP) is a new index reflecting lipid metabolism. Type 2 diabetes mellitus (T2DM) is a high risk factor for non-alcoholic fatty liver disease (NAFLD). The main purpose of this study was to explore the potential correlation between AIP and hepatic steatosis and hepatic fibrosis in American patients with T2DM. Methods: A cross-sectional survey was conducted using the dataset of the National Health and Nutrition Examination Survey (NHANES) from 2017 to 2020. Three models were constructed, and regression analysis was used to test the linear relationship between AIP and controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and NAFLD. AIP was divided into four levels and trend tests were performed. Restricted cubic spline plots (RCS) were used to describe the nonlinear relationship between them. All the above statistical analyses were weighted. Results: This study based on T2DM patients in the United States included 1170 people. In the multiple linear regression and logistic regression analysis, AIP*10 showed a significant positive correlation with CAP [β (95% CI), 31.83 (4.10~59.56), P = 0.033] and NAFLD [OR (95% CI), 1.16 (1.02~1.33), P = 0.035], and the trend test was statistically significant, but the relationship with LSM [β (95% CI), 0.04 (−1.35~1.42), P = 0.947] was not significant. RCS analysis showed an S-shaped nonlinear relationship between AIP and CAP (P-overall < 0.001, P-non-linear = 0.036), and as AIP increased, males had more severe hepatic steatosis than females. Conclusions: This study highlighted a substantial positive relationship between AIP and hepatic steatosis in patients with T2DM, and suggests that it may be used as a noninvasive indicator to predict the occurrence of NAFLD. However, no association was found between AIP and liver fibrosis.
文章引用:王帅帅, 阮士苗, 孙建秀, 张文忠. 美国2型糖尿病患者血浆致动脉粥样硬化指数(AIP)与肝脂肪变性和肝纤维化之间的关联:一项大型横断面研究[J]. 临床医学进展, 2024, 14(7): 1147-1159. https://doi.org/10.12677/acm.2024.1472125

参考文献

[1] Díaz, L.A., Fuentes-López, E., Ayares, G., Idalsoaga, F., Arnold, J., Márquez-Lomas, A., et al. (2022) The Establishment of Public Health Policies and the Burden of Non-Alcoholic Fatty Liver Disease in the Americas. The Lancet Gastroenterology & Hepatology, 7, 552-559. [Google Scholar] [CrossRef] [PubMed]
[2] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[3] Le, M.H., Yeo, Y.H., Li, X., Li, J., Zou, B., Wu, Y., et al. (2022) 2019 Global NAFLD Prevalence: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 20, 2809-2817.e28. [Google Scholar] [CrossRef] [PubMed]
[4] Byrne, C.D. and Targher, G. (2015) NAFLD: A Multisystem Disease. Journal of Hepatology, 62, S47-S64. [Google Scholar] [CrossRef] [PubMed]
[5] Younossi, Z.M., Golabi, P., de Avila, L., Paik, J.M., Srishord, M., Fukui, N., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71, 793-801. [Google Scholar] [CrossRef] [PubMed]
[6] Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., et al. (2009) Independent Predictors of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 7, 1224-1229.e2. [Google Scholar] [CrossRef] [PubMed]
[7] Fracanzani, A.L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., et al. (2008) Risk of Severe Liver Disease in Nonalcoholic Fatty Liver Disease with Normal Aminotransferase Levels: A Role for Insulin Resistance and Diabetes. Hepatology, 48, 792-798. [Google Scholar] [CrossRef] [PubMed]
[8] Ajmera, V., Cepin, S., Tesfai, K., Hofflich, H., Cadman, K., Lopez, S., et al. (2023) A Prospective Study on the Prevalence of NAFLD, Advanced Fibrosis, Cirrhosis and Hepatocellular Carcinoma in People with Type 2 Diabetes. Journal of Hepatology, 78, 471-478. [Google Scholar] [CrossRef] [PubMed]
[9] Dobiás̆ová, M. and Frohlich, J. (2001) The Plasma Parameter Log (TG/HDL-C) as an Atherogenic Index: Correlation with Lipoprotein Particle Size and Esterification Rate Inapob-Lipoprotein-Depleted Plasma (ferhdl). Clinical Biochemistry, 34, 583-588. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, Q., Zheng, D., Liu, J., Fang, L. and Li, Q. (2018) Atherogenic Index of Plasma Is a Novel Predictor of Non-Alcoholic Fatty Liver Disease in Obese Participants: A Cross-Sectional Study. Lipids in Health and Disease, 17, Article No. 284. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, J., Zhou, L., An, Y., Wang, Y. and Wang, G. (2022) The Atherogenic Index of Plasma: A Novel Factor More Closely Related to Non-Alcoholic Fatty Liver Disease than Other Lipid Parameters in Adults. Frontiers in Nutrition, 9, Article ID: 954219. [Google Scholar] [CrossRef] [PubMed]
[12] Tsochatzis, E.A., Gurusamy, K.S., Ntaoula, S., Cholongitas, E., Davidson, B.R. and Burroughs, A.K. (2011) Elastography for the Diagnosis of Severity of Fibrosis in Chronic Liver Disease: A Meta-Analysis of Diagnostic Accuracy. Journal of Hepatology, 54, 650-659. [Google Scholar] [CrossRef] [PubMed]
[13] Tang, A., Cloutier, G., Szeverenyi, N.M. and Sirlin, C.B. (2015) Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 1, Principles and Techniques. American Journal of Roentgenology, 205, 22-32. [Google Scholar] [CrossRef] [PubMed]
[14] Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., et al. (2005) Prospective Comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the Assessment of Fibrosis in Chronic Hepatitis C. Gastroenterology, 128, 343-350. [Google Scholar] [CrossRef] [PubMed]
[15] Eddowes, P.J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q.M., Sheridan, D., et al. (2019) Accuracy of Fibroscan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 156, 1717-1730. [Google Scholar] [CrossRef] [PubMed]
[16] Man, S., Lv, J., Yu, C., Deng, Y., Yin, J., Wang, B., et al. (2022) Association between Metabolically Healthy Obesity and Non-Alcoholic Fatty Liver Disease. Hepatology International, 16, 1412-1423. [Google Scholar] [CrossRef] [PubMed]
[17] Xue, Y., Xu, J., Li, M. and Gao, Y. (2022) Potential Screening Indicators for Early Diagnosis of NAFLD/MAFLD and Liver Fibrosis: Triglyceride Glucose Index-related Parameters. Frontiers in Endocrinology, 13, Article ID: 951689. [Google Scholar] [CrossRef] [PubMed]
[18] Peng, H., Pan, L., Ran, S., Wang, M., Huang, S., Zhao, M., et al. (2023) Prediction of MAFLD and NAFLD Using Different Screening Indexes: A Cross-Sectional Study in U.S. Adults. Frontiers in Endocrinology, 14, Article ID: 1083032. [Google Scholar] [CrossRef] [PubMed]
[19] Shen, Y., Wu, Y., Fu, M., Zhu, K. and Wang, J. (2023) Association between Weight-Adjusted-Waist Index with Hepatic Steatosis and Liver Fibrosis: A Nationally Representative Cross-Sectional Study from NHANES 2017 to 2020. Frontiers in Endocrinology, 14, Article ID: 1159055. [Google Scholar] [CrossRef] [PubMed]
[20] Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (nafld). Metabolism, 65, 1038-1048. [Google Scholar] [CrossRef] [PubMed]
[21] Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., et al. (2001) Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities. Gastroenterology, 120, 1183-1192. [Google Scholar] [CrossRef] [PubMed]
[22] George, D.K., Goldwurm, S., Macdonald, G.A., Cowley, L.L., Walker, N.I., Ward, P.J., et al. (1998) Increased Hepatic Iron Concentration in Nonalcoholic Steatohepatitis Is Associated with Increased Fibrosis. Gastroenterology, 114, 311-318. [Google Scholar] [CrossRef] [PubMed]
[23] Valenti, L., Fracanzani, A.L., Bugianesi, E., Dongiovanni, P., Galmozzi, E., Vanni, E., et al. (2010) HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 138, 905-912. [Google Scholar] [CrossRef] [PubMed]
[24] Strauss, R.S., Barlow, S.E. and Dietz, W.H. (2000) Prevalence of Abnormal Serum Aminotransferase Values in Overweight and Obese Adolescents. Journal of Pediatrics, 136, 0727-0733. [Google Scholar] [CrossRef] [PubMed]
[25] Sastre, J., Pallardó, F.V., Llopis, J., Furukawa, T., Vinã, J.R. and Viña, J. (1989) Glutathione Depletion by Hyperphagia-Induced Obesity. Life Sciences, 45, 183-187. [Google Scholar] [CrossRef] [PubMed]
[26] Lavine, J.E. (2000) Vitamin E Treatment of Nonalcoholic Steatohepatitis in Children: A Pilot Study. The Journal of Pediatrics, 136, 734-738. [Google Scholar] [CrossRef] [PubMed]
[27] Zhao, M., Zhao, L., Xiong, X., He, Y., Huang, W., Liu, Z., et al. (2020) TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma from Patients with Liver Steatosis, Inhibits Γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology, 158, 2266-2281.e27. [Google Scholar] [CrossRef] [PubMed]
[28] Begriche, K., Igoudjil, A., Pessayre, D. and Fromenty, B. (2006) Mitochondrial Dysfunction in NASH: Causes, Consequences and Possible Means to Prevent It. Mitochondrion, 6, 1-28. [Google Scholar] [CrossRef] [PubMed]
[29] Katsiki, N., Mikhailidis, D.P. and Mantzoros, C.S. (2016) Non-Alcoholic Fatty Liver Disease and Dyslipidemia: An Update. Metabolism, 65, 1109-1123. [Google Scholar] [CrossRef] [PubMed]
[30] Yin, B., Wu, Z., Xia, Y., Xiao, S., Chen, L. and Li, Y. (2023) Non-Linear Association of Atherogenic Index of Plasma with Insulin Resistance and Type 2 Diabetes: A Cross-Sectional Study. Cardiovascular Diabetology, 22, 157. [Google Scholar] [CrossRef] [PubMed]
[31] Cusi, K. (2020) Time to Include Nonalcoholic Steatohepatitis in the Management of Patients with Type 2 Diabetes. Diabetes Care, 43, 275-279. [Google Scholar] [CrossRef] [PubMed]
[32] Noureddin, M., Jones, C., Alkhouri, N., Gomez, E.V., Dieterich, D.T., Rinella, M.E., et al. (2020) Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-Effective: A Comprehensive Cost-Utility Analysis. Gastroenterology, 159, 1985-1987.e4. [Google Scholar] [CrossRef] [PubMed]
[33] Weston, S.R., Leyden, W., Murphy, R., Bass, N.M., Bell, B.P., Manos, M.M., et al. (2005) Racial and Ethnic Distribution of Nonalcoholic Fatty Liver in Persons with Newly Diagnosed Chronic Liver Disease. Hepatology, 41, 372-379. [Google Scholar] [CrossRef] [PubMed]
[34] Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. (2004) Prevalence of Hepatic Steatosis in an Urban Population in the United States: Impact of Ethnicity. Hepatology, 40, 1387-1395. [Google Scholar] [CrossRef] [PubMed]
[35] Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. (2011) Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. Gastroenterology, 140, 124-131. [Google Scholar] [CrossRef] [PubMed]